Patologia
Saila
University Hospital of Lausanne
Lausana, SuizaUniversity Hospital of Lausanne-ko ikertzaileekin lankidetzan egindako argitalpenak (10)
2021
-
Frequency and prognostic impact of alk amplifications and mutations in the european neuroblastoma study group (siopen) high-risk neuroblastoma trial (hr-nbl1)
Journal of Clinical Oncology, Vol. 39, Núm. 30, pp. 3377-3390
2020
-
Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report from the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group
Journal of Clinical Oncology, Vol. 38, Núm. 31, pp. 3685-3697
-
Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays’ and cross-validation with resections, in patients with, stage I–III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort
Modern Pathology, Vol. 33, Núm. 5, pp. 792-801
2019
2018
-
Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project
Journal of Thoracic Oncology, Vol. 13, Núm. 3, pp. 413-425
2017
2015
-
Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification
British Journal of Cancer, Vol. 112, Núm. 2, pp. 290-295
2014
-
Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape project
Journal of Clinical Oncology, Vol. 32, Núm. 25, pp. 2780-2787
2011
-
A multilocus technique for risk evaluation of patients with neuroblastoma
Clinical Cancer Research, Vol. 17, Núm. 4, pp. 792-804
2009
-
Influence of neuroblastoma stage on serum-based detection of MYCN amplification
Pediatric Blood and Cancer, Vol. 53, Núm. 3, pp. 329-331